Sodium (2R, 5S, 13Ar) -7, 9-Dioxo-10- ( (2,4,6-Trifluorobenzyl) Carbamoyl) -2, 3, 4, 5, 7, 9, 13, 13A-Octahydro-2, 5-Methanopyrido [1',2' : 4.5]Pyrazino [2, 1-B]Oxazepin-8-Olate
Patent No. EP3157932 (titled "Sodium (2R, 5S, 13Ar) -7, 9-Dioxo-10- ( (2,4,6-Trifluorobenzyl) Carbamoyl) -2, 3, 4, 5, 7, 9, 13, 13A-Octahydro-2, 5-Methanopyrido [1',2' : 4.5]Pyrazino [2, 1-B]Oxazepin-8-Olate") was filed by Gilead Sciences on Jun 19, 2015. The application was issued on Jan 10, 2018.
Patent Summary
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP3157932
- Application Number
- EP15739063A
- Filing Date
- Jun 19, 2015
- Status
- Revoked
- Jun 28, 2019
- Publication Date
- Jan 10, 2018
- External Links
- Slate, Register , Google Patents